Aspirin! Because You May Not Need To F%#k Cancer After All.

wedopainkilling There are lots of reasons to be angry about cancer, but when you find out just how effective aspirin is, as both a preventative measure and treatment (even cure), you might move from anger and suffering, skipping past worry and sadness, straight on up to murderous intent.

“Observational studies show that regular use of aspirin reduces the long-term risk of several cancers and the risk of distant metastasis. Results of methodologically rigorous studies are consistent with those obtained from randomised controlled trials…” (Algra AM, Rothwell PM, 2012)

“We find that ASA [aspirin] not only prevents breast tumor cell growth…and tumor growth…but also significantly reduces the self-renewal capacity and growth of breast tumor-initiating cells/breast cancer stem cells…and delays the formation of a palpable tumor.” (Maity G, et al., 2015)

“The goal in this study was to investigate the antitumor effect of aspirin in glioblastoma cells and the molecular mechanism involved in its antineoplastic activities…results suggest that aspirin is a potent antitumor agent, and that it exerts its antineoplastic action by inhibition of the β-catenin/TCF signaling pathway in glioma cells.” (Lan F, et al., 2011)

Daily aspirin has been shown to reduce the long-term risk of death due to cancer, as well as short term cancer incidence and mortality. And aspirin has been found to be protective in relation to melanoma, leukemia, colorectal, oesophageal, endometrial, breast, lung, prostate, liver, skin, head and neck, laryngeal, ovarian, pancreatic, gastric, lung, and brain cancer.

Of course aspirin isn’t only effective in relation to cancer reduction, because that isn’t how biology and metabolic function works, and – contrary to the modern mainstream medical myth – cancer has long been understood to be a biological/metabolic issue.

“…results revealed that the targets of aspirin and its metabolite are associated with metabolic function or immunity and are therefore involved in aging modulation. Our previous study and our current results show that multiple pathways are involved in the regulation of the aging process by aspirin.” ( Xiao-Bing Huang, et al., 2017)

“…aspirin…an anti-inflammatory agent…is currently used extensively as a cardioprotective and antithrombotic agent…regular use of aspirin is associated with a reduced risk for colorectal, oesophageal, breast, lung, prostate, liver and skin cancers…both constituent groups of aspirin…the acetyl and salicylate moieties have distinct targets that…contribute to its anticancer effects.” (L Alfonso, et al., 2014)

“Post-diagnosis use of aspirin in patients with gastrointestinal tract malignancies is associated with increased survival in cancers with different sites of origin and biology.” (M A Frouws, et al., 2017)

“…aspirin inhibits protein aggregation and the ensuing toxicity of aggregates through its acetyl-donating activity. This mechanism may contribute to the neuro-protective, cardio-protective, and life-prolonging effects of aspirin.” (Ayyadevara S, et al., 2017)

In fact aspirin has been shown to be helpful with almost any physiological problem arising out of excessive exposure to chronic and acute stress and inflammation, and inflammatory stress is a fundamental driver of cancer.

The substances that rise systemically, under excessively stressful conditions (like cortisol, serotonin, nitric oxide and estrogen), and that are known to be involved in the development and spread of cancer, interfere with metabolic, as well as immune and nervous system function, and promote inflammatory and degenerative disease in general.

“…findings suggest that aspirin use may prevent incident breast, colon, pancreatic, and ovarian cancer in elderly women.” (Lisa E. Vaughan, et al., 2016)

“…aspirin…appears to reduce staphylococcal virulence…aspirin may have the potential to be an effective adjunctive agent in the treatment of serious hospital- or community-acquired S. aureus infections.” (Leon Iri Kupferwasser, et al., 2003)

“Aspirin can reduce oxidative stress and protect against oxidative damage….evidence suggests…beneficial effects of aspirin…in mood disorders and schizophrenia, and…data suggests…aspirin is associated with a reduced risk of AD [Alzheimer’s].” (Michael Berk, et al., 2013)

“Aspirin therapy, in doses commonly employed in practice, has an excellent safety profile in rheumatoid arthritis…Aspirin therapy merits reconsideration as adjunctive therapy for the management of rheumatoid arthritis.” (Fries JF, et al., 1993)

Aspirin helps to protect against stress by improving the function of metabolism. One way it does this, is by protecting against the escalation of inflammation (and related symptoms) arising as a result of excessive stress and interference with thyroid energy systems.

Suppression of thyroid energy metabolism promotes, and is promoted by inflammation. Inflammation and thyroid dysfunction are interconnected with a variety of biological issues. Issues including cellular and mitochondrial dysfunction, interference with enzyme activity, and inhibition of the ability to use sugar as fuel, combined with greater exposure to free fatty acids, lipid peroxidation, and oxidative damage. Aspirin can have beneficial effects in relation to all of these things, and all of these things have been shown to be involved in the development of cancer, and metabolic illness in general.

“Epidemiologic and clinical studies indicate that inflammation is correlated with an increased risk of recurrence in breast cancer patients…multiple meta-analyses showed that patients with cardiovascular diseases treated with…aspirin, have reduced cancer risk.” (Shilpi Saha, et al., 2016)

“Our observations confirm that low-T3 levels are commonly found in ESRD [end-stage renal disease] patients on PD [Peritoneal dialysis] and show that this alteration is linked to low-grade inflammation and death in this population.” (Giuseppe Enia, et al., 2007)

“Neutrophils have a fundamental role in inflammatory responses…neutrophils specifically support metastatic initiation…neutrophil-derived leukotrienes aid the colonization of distant tissue by selectively expanding the sub-pool of cancer cells that retain high tumorigenic potential…inhibition of the leukotriene-generating enzyme arachidonate 5-lipoxygenase…abrogates neutrophil pro-metastatic activity and consequently reduces metastasis.” (Wculek SK, Malanchi I., 2015)

“…we provide new molecular mechanisms underlying the pleiotropic response to ASA by demonstrating that this NSAID promotes the formation of endogenous anti-inflammatory compounds…and modulates 5-LO [5-lipoxygenase] activity…decreasing 5-LO activity in macrophages…a central role in the control of inflammation…” (ANNA PLANAGUMÀ, et al., 2002)

Looking at the potential benefits of aspirin in relation to stress and basic metabolic function, is also a good way to understand the big picture reasons why aspirin helps protect against (and treat) heart disease and stroke, as well as also depression, diabetes and insulin resistance. And then there’s its use for the improvement in Alzheimer’s, or just for neuroprotection in general. Not to mention its effectiveness in relation to hypertension, pregnancy and fertility issues, and an almost endless list of other symptoms and conditions.

“…neurological disorders, including Alzheimer’s…Huntington’s…and Parkinson’s disease…are characterized by accumulation of insoluble protein aggregates…aspirin inhibits protein aggregation…” (Ayyadevara S, et al., 2017)

“LDA [low dose aspirin] increased the chances of clinically recognized pregnancy and live birth in women with moderately elevated hsCRP and prior pregnancy loss.” (Lindsey A. Sjaarda, et al., 2017)

There is a huge amount of quality scientific experimentation (available for pretty much anybody to look at), which demonstrates the many powerful ways aspirin can protect against disease – including regarding cancer – and not just simply as a preventative measure.

“We conducted a prospective study from 1992 through 1999 among 28 283 postmenopausal women…There was a trend of decreasing risk of pancreatic cancer incidence with increasing frequency of aspirin use per week.” (Anderson KE, et al., 2002)

“…patients in the study had all stages of cancer at diagnosis—“When you look at the effects of aspirin stratified by cancer stage, you still see the same positive effects.”” (Susman, Ed, 2015)

“Daily aspirin reduced deaths due to several common cancers during and after the trials. Benefit increased with duration of treatment and was consistent across the different study populations…” (Rothwell PM, et al., 2011)

Scientists (working for governments and pharmaceutical companies) all over the world have attempted to use the physiological effects of aspirin, as a model to assist in finding a cure for cancer. But is that really all that they are looking for?

“…a novel, gastrointestinal-safe phosphatidylcholine (PC)-associated aspirin, PL2200 Aspirin, possesses the same or more pronounced actions versus unmodified aspirin with regard to antiplatelet effects…and chemoprevention.” (Lenard M. Lichtenberger, et al., 2017)

There seems to be an ongoing race to develop new products modeled on aspirin (which would provide similar positive results in relation to cancer), but different enough to be able to be patented, perhaps as a means to making oodles and oodles of dinero. I don’t know, but it seems like aspirin already works, exactly the way it is.

And unfortunately, there is no guarantee that whatever is produced will match the manner in which aspirin (tried and tested for many decades) works, to safely provide physiological protection, including chemotherapeutic benefit. But it’s hard to make the big money out of something so widely and cheaply available, even if it is superior to more recent products.

“…we report a significant reduction in HNC [head and neck cancer] risk with aspirin use, with the strongest protective effect for laryngeal cancers. No association was observed between HNC and ibuprofen use.” (Wilson JC, et al., 2013)

Many of the substances which are known to rise systemically in times of high and ongoing stress – cortisol, serotonin, estrogen, nitric oxide, lactate, growth hormone, prolactin, the polyunsaturated free fatty acids and the prostaglandins – do so because of the ways that too much biochemical stress exposure can interfere with metabolism.

The stress substances are involved in the promotion of inflammatory conditions, and are known to rise under circumstances where thyroid energy production is suppressed. Aspirin has been demonstrated to be able to reduce exposure to the disease promoting stress materials.

“…results suggest that postmenopausal women who regularly use aspirin…may have lower estrogen levels…We observed significant inverse associations between total NSAID use and concentrations of estradiol and free estradiol…analgesics that decrease aromatase activity via suppression of COX expression and prostaglandin synthesis also may decrease estrogen concentrations” (Gates MA, et al., 2010)

“The inhibition of iNOS expression by aspirin was further associated with a reduced ability…to produce TNF-alpha. This study could provide new mechanisms of action for aspirin in the treatment of the inflammation-related…diseases.” (Sánchez de Miguel L, et al., 1999)

“The results clearly show that…ASA ingestion significantly blunted the increased serum ACTH, beta-endorphin, cortisol, and GH [growth hormone] levels…and was associated with reduced cortisol concentration…[and] a significantly reduced total PRL [prolactin] response to stress condition[s]…” (Di Luigi L, et al., 2001)

“Aspirin (ASA), a platelet aggregation inhibitor, inhibits 5-HT [serotonin] release from platelets…Plasma 5-HT was measured by high-performance liquid chromatography…The effects of ASA was associated with a reduction of 5-HT.” (Shen L, et al., 2011)

The prostaglandins, are produced from polyunsaturated fats (PUFAs), mediated by the cyclooxygenase (COX) enzymes, and the inhibition of this pathway has been shown to protect against cancer metastasis. Low dose aspirin inhibition of COX1 (preventing the formation of prostaglandin H2, and therefore TXA2) was demonstrated to be able to effectively inhibit lung cancer metastasis from melanoma and breast cancer cell lines.

“Because metastasis is associated with the majority of cancer-related deaths, its prevention is a clinical aspiration. Prostanoids are a large family of bioactive lipids derived from the activity of cyclooxygenase-1 (COX-1) and COX-2. Aspirin impairs the biosynthesis of all prostanoids through the irreversible inhibition of both COX isoforms.” (Serena Lucotti, et al., 2019)

Prostaglandins also promote the aromatase enzyme, responsible for a large quantity of an increased exposure to estrogen, and aspirin helps to limit aromatase activity, protecting against cancer development and spread.

“…use of aspirin could contribute to the suppression of aromatase activity, reducing the intra-mammary prostaglandin production, and thus, estrogen production…E2 prostaglandin (PGE2) stimulates the transcription of aromatase, increasing the estrogen levels…contributing to the progression of…BC [breast cancer].” (Nadia J. Jacobo-Herrera, et al., 2014)

Avoidance of the PUFAs, powerful drivers of inflammation and thyroid energy system dysfunction, is probably the most effective way of protecting against the cancer promoting impact of the production of prostaglandins, as well as numerous other inflammatory stress promoting substances, including aromatase. The PUFAs and their byproducts, are also a big part of what can damage cellular production of energy under stress.

And all of this ties together, because a lack of energy supply (in combination with continuous exposure to excessive levels of the stress substances and promoters of inflammation) is known to be a significant driving force behind the onset, and development of cancer. Sugar is an optimal energy source, and a fundamental anti-stress substance. Many things related to stress and inflammation, interfere with the optimal use of sugar for energy.

Ongoing stress and interference with energy system function also promotes bacterial endotoxin (LPS) related issues, and endotoxin (via TLR activation) promotes inflammation and thyroid energy system dysfunction, and has been shown to be directly involved in the spread and metastasis of almost every kind of cancer. Aspirin can also protect against cancer progression by inhibiting the effects of LPS/TLR.

“The results of our study indicate that LPS origin from intestinal flora may promote the metastasis of colon cancer to liver and aspirin may inhibit the metastasis of colon cancer by inhibiting the expression of TLR4.” (Jun Ying, et al., 2018)

The substances of stress and inflammation (including serotonin, estrogen, nitric oxide, and the breakdown products of the PUFAs), interact with circulating bacterial endotoxin, to powerfully increase the inhibition of energy production throughout the system. Increased systemic circulation of the stress substances, can create a vicious circle of stress promotion and inflammatory disease.

“We show that the targeted therapy with iNOS inhibitors is able to inhibit not only tumor cell proliferation but also…self-renewal and migration, reducing tumor growth, tumor initiation, and the number of lung metastases…” (Granados-Principal S, et al., 2015)

“5-HT [serotonin] stimulates proliferation of PC cells and 5-HTR1A antagonists inhibit proliferation. Thus, we propose that 5-HT has an important role in tumor progression…” (Dizeyi N, et al., 2004)

“17-β-estradiol can act as a carcinogenic agent without the need of the ERα…The knowledge that breast cancer in women is associated with prolonged exposure to high levels of estrogens gives relevance to this model of estrogen induced carcinogenesis.” (Russo J, Russo IH. et al., 2006)

“Dietary soy isoflavones increase metastasis to lungs in a model of breast cancer and a recent study reported significantly increased cell proliferation in breast cancer patients who used soy supplementation. The soy isoflavone daidzein is a major food-derived phytoestrogen that is structurally similar to estrogen.” (Jana Koo, et al., 2015)

Even when enough sugar is being provided (and unused supplies are available), ongoing exposure to inflammation and the substances of stress, can interfere with the proper utilization of available sugar for energy, and this can make a return to normal function difficult. Aspirin can help protect against the things that interfere with the use of sugar for fuel, and for stress reduction.

The relationship between diabetes and cancer is not coincidental. The substances of stress that promote exposure to the PUFAs and their breakdown products, interfere directly with proper blood sugar regulation and thyroid energy production, and are responsible for many varieties of inflammatory stress illness. Aspirin can be protective at a basic metabolic level. Aspirin protects against excessive exposure to the stress substances and polyunsaturated free fatty acids, central factors in inflammatory disease progression.

“Insulin-stimulated whole-body glucose uptake was decreased by 37% with the lipid infusion…Salicylate pretreatment prevented these decreases…Salicylate pretreatment also prevented the lipid-induced decreases in insulin-stimulated skeletal muscle glucose metabolism…salicylate pretreatment prevents lipid-induced skeletal muscle insulin resistance…these results provide important new insights into the mechanism of fat-induced insulin resistance…and suggest a potentially novel class of therapeutic agents for type 2 diabetes.” (Jason K. Kim, et al., 2001)

“…high dose aspirin treatment improved both fasting and postprandial hyperglycemia in patients with type 2 diabetes, an effect that could be attributed to decreased basal rates of hepatic glucose production, enhanced peripheral insulin sensitivity, and decreased insulin clearance.” (Hundal RS, et al., 2002)

“In fasting conditions, the lipolytic activity of adipocytes is stimulated by catecholamines…aspirin has been reported to reduce catecholamine-stimulated lipolysis…In addition…aspirin reduces release of FA [fatty acids] from adipose tissue directly via inhibition of TNFα-induced lipolysis…” (van Diepen JA, et al., 2011)

It’s safe to say that one way aspirin helps to protect against inflammation and disease, is by improving the function of metabolic energy systems. This then helps protect against stress, and limits interference with cellular performance, often resulting from excessive exposure to cancer promoting inflammatory substances, such as cortisol, estrogen, nitric oxide and the breakdown products of PUFAs.

“Since FAs [fatty acids] are essential for cancer cell proliferation, limiting their availability could provide a therapeutic strategy. From the perspective of lipid metabolism, limiting FA availability could be achieved in several ways…” (Currie E, Schulze A, et al., 2013)

“Abnormal lipid metabolism is a hallmark of tumorigenesis. Hence, the alterations of metabolism enhance the development of hepatocellular carcinoma (HCC)…Therapeutically, aspirin is potentially available for HCC through controlling abnormal lipid metabolism.” (Yang G, et al., 2017)

“…stress…caused brain expression of iNOS, an increase in plasma glutamate and brain TNF-alpha, induction of oxidative indicators in brain and a fall in brain ATP levels….aspirin…inhibited all these effects caused by stress…” (De Cristóbal J, et al., 2002)

“Arachidonic acid (ARA) is metabolized by cyclooxygenase (COX) and cytochrome P450 to produce proangiogenic metabolites. Specifically, epoxyeicosatrienoic acids (EETs) produced from the P450 pathway are angiogenic, inducing cancer tumor growth.” (Rand AA, et al., 2017)

“Aspirin is an anti-inflammatory drug, peroxyl radical scavenger, and antioxidant agent that inhibits phospholipases, nitric oxide synthetases, and cyclooxygenase enzymes…Aspirin decreased lipid peroxidation…we demonstrated the potential effects of aspirin on biochemical and neurobehavioral recovery…” (Hamed Reihani Kermani, MD, et al., 2016)

You can see why aspirin is potentially threatening. For starters, if enough people were convinced of its protective ability in relation to cancer, that could damage the widely held belief, that ‘modern medicine’ is always progressing towards greater understanding of the causes of (and best ways of dealing with) serious illness.

But just think about what’s been known for decades about the benefits of aspirin, and consider the fact that the dangers of aspirin have been shown in many cases to be overblown.

“On multivariate analysis…aspirin was protective against in-hospital mortality, rebleeding, and predictive of a shorter hospital stay…being on anticoagulants was predictive of in-hospital complications and severe bleeding. Compared to those not taking any antithrombotics, patients who bled on aspirin were less likely to die in hospital of uncontrolled gastrointestinal bleeding and systemic cancer…” (Wehbeh A, et al., 2015)

“Whether or not low-dose aspirin is ever responsible for peptic ulceration is uncertain…intestinal mucosal damage…appears to improve rapidly during continued aspirin taking long-term…low-dose prophylactic aspirin would seem to be remarkably safe, probably far safer than implied…” (P. Elwood, G. Morgan, 2014)

There’s no end to the amount of research that can be done, but it won’t change the fact that aspirin already works right now. So what are we waiting for?

“…aspirin suppressed prostate cancer cell invasion by reducing MMP-9 activity and uPA expression through decreasing of IKK-β-mediated NF-κB activation, indicating that the ability of aspirin to inhibit cell invasion might be useful in the chemoprevention of metastatic prostate cancer.” (Shi C, et al., 2017)

“…salicylate…exhibit anti-tumor activity against…leukemia…We…tested…other NSAIDs, including acetaminophen and indomethacin…but did not detect any inhibitory activity…salicylate may be useful for treating inflammation, diabetes, neurodegenerative disease, and other pathologies…”  (Shirakawa K, et al., 2016)

“Postmenopausal women who used ASA had a significantly lower risk of melanoma, and longer duration of ASA use was associated with greater protection.” (Gamba CA, et al., 2013)

Acknowledging the truth about how aspirin works, might add weight to ‘alternative’ (biologically valid) explanations, for what makes cancer develop and spread. This might then cause a flow-on effect, unmasking ineffective and harmful products or treatment methodologies, across the board. That’s not good for business.

I’m not a doctor or health practitioner, and I’m not here to give medical or dietary advice.  Read the arguments. Have a look through the science. Decide for yourself. (Warning – Consult your local expert/doctor before making health/medical/pharmaceutical decisions.)

But there does seem to be good reasons, why it makes sense to see cancer – rather than as simply some kind of genetically predetermined disease – as a reasonably normal reaction of individual cells and whole systems (attempting to keep us alive and functioning), in the face of a certain amount of exposure to ‘unnatural’, and excessively stressful and inflammatory conditions. Looking at it this way can change a lot of things.

At moments like this it seems more appropriate – rather than saying ‘f%#k cancer’ – to say ‘f&$k the cancer industry’, and all related organizations and industries, which have helped muddy the waters surrounding the true causes of (and really effective approaches to protecting against or even treating) cancer, in the name of greed, power and status.

“The present meta-analysis, which involves approximately 300,000 participants from 16 studies, has confirmed the antineoplastic effects of NSAIDs in multi-cancer metastasis…aspirin was the most predominant NSAID given to patients.” ( Xiaoping Zhao, Zhi Xu & Haoseng Li, 2017)

You see, if everything can cause cancer, and nothing can cure cancer, it becomes easier to get away with selling things that actually do cause cancer, and things that really can’t cure cancer, whilst at the same time avoiding competition from the things that don’t cause cancer and things that really do cure cancer. Was that clear?

See More Here

Lab Invest. 2015 Jul;95(7):702-17. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Maity G, De A, Das A, Banerjee S, Sarkar S, Banerjee SK.

J Clin Invest. 2019 Mar 25;129(5):1845-1862. Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A2. Lucotti S, Cerutti C, Soyer M, Gil-Bernabé AM, Gomes AL, Allen PD, Smart S, Markelc B, Watson K, Armstrong PC, Mitchell JA, Warner TD, Ridley AJ, Muschel RJ.

Cancer Res. 2016 Apr 1;76(7):2000-12. Aspirin Suppresses the Acquisition of Chemoresistance in Breast Cancer by Disrupting an NFκB–IL6 Signaling Axis Responsible for the Generation of Cancer Stem Cells. Shilpi Saha, Shravanti Mukherjee, Poulami Khan, Kirti Kajal, Minakshi Mazumdar, Argha Manna, Sanhita Mukherjee, Sunanda De, Debarshi Jana, Diptendra K. Sarkar and Tanya Das

Mediators Inflamm. 2016;2016:6757154. Thyroid Hormones, Oxidative Stress, and Inflammation. Mancini A, Di Segni C, Raimondo S, Olivieri G, Silvestrini A, Meucci E, Currò D.

. Aspirin-triggered proresolving mediators stimulate resolution in cancer. Molly M. Gilligan, Allison Gartung, Megan L. Sulciner, Paul C. Norris, Vikas P. Sukhatme, Diane R. Bielenberg, Sui Huang, Mark W. Kieran, Charles N. Serhan, and Dipak Panigrahy.

Cancer Epidemiol Biomarkers Prev. 2002 Mar;11(3):275-9. A Dose-finding Study of Aspirin for Chemoprevention Utilizing Rectal Mucosal Prostaglandin E2 Levels as a Biomarker. Dory Sample, Michael Wargovich, Susan M. Fischer, Nikil Inamdar, Peter Schwartz, Xuemei Wang, Kim-Anh Do and Frank A. Sinicrope.

PLoS One. 2017 Sep 14;12(9):e0184027. Aspirin increases metabolism through germline signalling to extend the lifespan of Caenorhabditis elegans. Huang XB, Mu XH, Wan QL, He XM, Wu GS, Luo HR.

Cancer Causes Control. 2016 Nov;27(11):1395-1402. Aspirin use and the incidence of breast, colon, ovarian, and pancreatic cancers in elderly women in the Iowa Women’s Health Study. Vaughan LE, Prizment A, Blair CK, Thomas W, Anderson KE.

J Clin Invest. 1996 Jun 15;97(12):2859-65. Mechanism of free fatty acid-induced insulin resistance in humans. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI.

J Natl Cancer Inst. 2002 Aug 7;94(15):1168-71. Association between nonsteroidal anti-inflammatory drug use and the incidence of pancreatic cancer. Anderson KE, Johnson TW, Lazovich D, Folsom AR.

BMC Cancervolume 18, Article number: 288 (2018). Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. Yan Qiao, Tingting Yang, Yong Gan, Wenzhen Li, Chao Wang, Yanhong Gong & Zuxun Lu.

Ann Oncol. 2015 Feb;26(2):441-2. The harms of low-dose aspirin prophylaxis are overstated. Elwood P, Morgan G.

J Natl Cancer Inst. 2007 Jun 6;99(11):881-9. Association of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortality. Bardia A, Ebbert JO, Vierkant RA, Limburg PJ, Anderson K, Wang AH, Olson JE, Vachon CM, Cerhan JR.

Breast Cancer Res Treat. 2011 Feb;126(1):149-55. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR.

Cancer Epidemiol Biomarkers Prev. 2002 Dec;11(12):1586-91. Association of aspirin and nonsteroidal anti-inflammatory drug use with breast cancer. Johnson TW, Anderson KE, Lazovich D, Folsom AR.

Prostaglandins. 1982 May;23(5):731-41. Aspirin inhibits arachidonic acid metabolism via lipoxygenase and cyclo-oxygenase in hamster isolated lungs. Paajanen H, Männistö J, Uotila P.

Cancer Epidemiol Biomarkers Prev. 2010 Feb;19(2):435-42. Nonsteroidal anti-inflammatory drugs and risk for ovarian and endometrial cancers in the Iowa Women’s Health Study. Prizment AE, Folsom AR, Anderson KE.

Dig Dis Sci. 2015 Jul;60(7):2077-87. Aspirin Has a Protective Effect Against Adverse Outcomes in Patients with Nonvariceal Upper Gastrointestinal Bleeding. Wehbeh A, Tamim HM, Abu Daya H, Abou Mrad R, Badreddine RJ, Eloubeidi MA, Rockey DC, Barada K.

Chemopreventive effect of long-term use of low-dose aspirin on lung cancer risk: A nationwide study considering competing risk. Eun Mi Chun, Shinhee Ye, Eun-Hee Ha.

Lancet. 2012 Apr 28;379(9826):1602-12. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, Lee R, Belch JF, Wilson M, Mehta Z, Meade TW.

Eur J Appl Physiol. 2003 Apr;89(2):177-83. The influence of aspirin on exercise-induced changes in adrenocorticotrophic hormone (ACTH), cortisol and aldosterone (ALD) concentrations. Przybyłowski J, Obodyński K, Lewicki C, Kuźniar J, Zaborniak S, Drozd S, Czarny W, Garmulewicz M.

Lancet Oncol. 2012 May;13(5):518-27. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Algra AM, Rothwell PM.

Prostate. 2004 May 15;59(3):328-36. Expression of serotonin receptors and role of serotonin in human prostate cancer tissue and cell lines. Dizeyi N, Bjartell A, Nilsson E, Hansson J, Gadaleanu V, Cross N, Abrahamsson PA.

Prostaglandins Leukot Essent Fatty Acids. 2017 Oct;125:8-13. Low dose aspirin increases 15-epi-lipoxin A4 levels in diabetic chronic kidney disease patients. Goicoechea M, Sanchez-Niño MD, Ortiz A, García de Vinuesa S, Quiroga B, Bernis C, Morales E, Fernández-Juarez G, de Sequera P, Verdalles U, Verde E, Luño J.

Cell Rep. 2018 Apr 24;23(4):974-982. Obesity Suppresses Cell-Competition-Mediated Apical Elimination of RasV12-Transformed Cells from Epithelial Tissues. Sasaki A, Nagatake T, Egami R, Gu G, Takigawa I, Ikeda W, Nakatani T, Kunisawa J, Fujita Y.

The Journal of Clinical Endocrinology & Metabolism, Volume 102, Issue 5, 1 May 2017, Pages 1495–1504. Preconception Low-Dose Aspirin Restores Diminished Pregnancy and Live Birth Rates in Women With Low-Grade Inflammation: A Secondary Analysis of a Randomized Trial.  Lindsey A. Sjaarda, Rose G. Radin, Robert M. Silver, Emily Mitchell, Sunni L. Mumford, Brian Wilcox, Noya Galai, Neil J. Perkins, Jean Wactawski-Wende, Joseph B. Stanford, Enrique F. Schisterman.

Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Nan Chiang, Edmund A. Bermudez, Paul M. Ridker, Shelley Hurwitz, and Charles N. Serhan.

Free Radic Biol Med. 1995 Mar;18(3):585-91. Aspirin inhibits both lipid peroxides and thromboxane in preeclamptic placentas. Wang Y, Walsh SW.

Tohoku J Exp Med. 1979 Jan;127(1):85-95. Changes in thyroid hormones by treatment with aspirin and prednisolone in subacute thyroiditis with hyperthyroidism. Yamamoto M, Saito S, Kaise K, Kaise N, Yoshida K, Yoshinaga K.

Ann Oncol. 2012 Jun;23(6):1403-15.  Aspirin and cancer risk: a quantitative review to 2011. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C.

J Natl Cancer Inst. 2014 Feb;106(2):djt431. Aspirin, nonaspirin nonsteroidal anti-inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a pooled analysis in the Ovarian Cancer Association Consortium. Trabert B1, Ness RB, Lo-Ciganic WH, Murphy MA, Goode EL, Poole EM, Brinton LA, Webb PM, Nagle CM, Jordan SJ; Australian Ovarian Cancer Study Group, Australian Cancer Study (Ovarian Cancer), Risch HA, Rossing MA, Doherty JA, Goodman MT, Lurie G, Kjær SK, Hogdall E, Jensen A, Cramer DW, Terry KL, Vitonis A, Bandera EV, Olson S, King MG, Chandran U, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pearce CL, Pike MC, Berchuck A, Schildkraut JM, Wentzensen N; Ovarian Cancer Association Consortium.

J Clin Invest. 2002 May;109(10):1321-6. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE, Shulman GI.

BMB Rep. 2014 Jan;47(1):45-50. Aspirin inhibits lipopolysaccharide-induced COX-2 expression and PGE2 production in porcine alveolar macrophages by modulating protein kinase C and protein tyrosine phosphatase activity. Duan Y, Chen F, Zhang A, Zhu B, Sun J, Xie Q, Chen Z.

Biology of Reproduction, Volume 99, Issue 2, August 2018, Pages 422–432. The intervention effect of aspirin on a lipopolysaccharide-induced preeclampsia-like mouse model by inhibiting the nuclear factor-κB pathway. Guanlin Li, Liyang Ma, Li Lin, Yan-ling Wang, Huixia Yang.

Am J Physiol Endocrinol Metab. 2011 Dec;301(6):E1099-107. Aspirin reduces hypertriglyceridemia by lowering VLDL-triglyceride production in mice fed a high-fat diet. van Diepen JA, Vroegrijk IO, Berbée JF, Shoelson SE, Romijn JA, Havekes LM, Rensen PC, Voshol PJ.

Nature. 2015 Dec 17;528(7582):413-7. Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Wculek SK, Malanchi I.

Am J Physiol Gastrointest Liver Physiol. 2005 Oct;289(4):G731-8. Role of mitochondria in aspirin-induced apoptosis in human gastric epithelial cells. Redlak MJ, Power JJ, Miller TA.

Acta Obstet Gynecol Scand. 2013 Mar;92(3):245-55. Nonsteroidal anti-inflammatory drugs and risk of ovarian cancer: systematic review and meta-analysis of observational studies. Baandrup L, Faber MT, Christensen J, Jensen A, Andersen KK, Friis S, Kjaer SK.

Sci Rep. 2015 Oct 21;5:15460. Aspirin might reduce the incidence of pancreatic cancer: A meta-analysis of observational studies. Zhang YP, Wan YD, Sun YL, Li J, Zhu RT.

Antioxid Redox Signal. 2017 Dec 10;27(17):1383-1396. Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation. Ayyadevara S, Balasubramaniam M, Kakraba S, Alla R, Mehta JL, Shmookler Reis RJ.

Breast Cancer Res. 2015 Feb 22;17:25. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer. Granados-Principal S, Liu Y, Guevara ML, Blanco E, Choi DS, Qian W, Patel T, Rodriguez AA, Cusimano J, Weiss HL, Zhao H, Landis MD, Dave B, Gross SS, Chang JC.

Carcinogenesis. 2016 Jun;37(6):616-624. The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice. Guo Y, Liu Y, Zhang C, Su ZY, Li W, Huang MT, Kong AN.

Mayo Clin Proc. 2016 Jan;91(1):71-80. Personalizing Aspirin Use for Targeted Breast Cancer Chemoprevention in Postmenopausal Women. Bardia A, Keenan TE, Ebbert JO, Lazovich D, Wang AH, Vierkant RA, Olson JE, Vachon CM, Limburg PJ, Anderson KE, Cerhan JR.

Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13182-7. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Ghosh J, Myers CE.

J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):89-96. THE ROLE OF ESTROGEN IN THE INITATION OF BREST CANCER. Russo J, Russo IH.

Acta Pharmacologica Sinica volume 40, pages122–132 (2019). Aspirin inhibits the proliferation of hepatoma cells through controlling GLUT1-mediated glucose metabolism. Yun-xia Liu, Jin-yan Feng, Ming-ming Sun, Bo-wen Liu, Guang Yang, Ya-nan Bu, Man Zhao, Tian-jiao Wang, Wei-ying Zhang, Hong-feng Yuan & Xiao-dong Zhang

Cell Biochem Biophys. 2011 Sep;61(1):23-31. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. Shen L, Shen J, Pu J, He B.

Scientific Reports volume 7, Article number: 11549 (2017). Aspirin inhibits LPS-induced macrophage activation via the NF-κB pathway. Yitong Liu, Silian Fang, Xiaoyan Li, Jie Feng, Juan Du, Lijia Guo, Yingying Su, Jian Zhou, Gang Ding, Yuxing Bai, Songling Wang, Hao Wang & Yi Liu

Lancet. 2011 Jan 1;377(9759):31-41. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW.

Cancer Epidemiol Biomarkers Prev. 2009 Oct;18(10):2726-33. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence–data from a randomized clinical trial. Barry EL, Sansbury LB, Grau MV, Ali IU, Tsang S, Munroe DJ, Ahnen DJ, Sandler RS, Saibil F, Gui J, Bresalier RS, McKeown-Eyssen GE, Burke C, Baron JA.

J Cell Mol Med. 2016 Jul;20(7):1307-18. Aspirin induces Nrf2‐mediated transcriptional activation of haem oxygenase‐1 in protection of human melanocytes from H2O2‐induced oxidative stress. Jian Z, Tang L, Yi X, Liu B, Zhang Q, Zhu G, Wang G, Gao T, Li C.

Cancer. 2013 Apr 15;119(8):1562-9. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women’s Health Initiative. Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, Sinha AA, Asgari MM, Sturgeon S, Tang JY.

Oncol Rep. 2014 Aug;32(2):451. Clinical evidence of the relationship between aspirin and breast cancer risk (Review). Nadia J. Jacobo-Herrera Carlos Pérez-Plasencia Elizabeth Camacho‑Zavala Gabriela Figueroa González Eduardo López Urrutia Verónica García‑Castillo Alejandro Zentella-Dehesa

Nephrology Dialysis Transplantation, Volume 22, Issue 2, February 2007, Pages 538–544. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Giuseppe Enia, Vincenzo Panuccio, Sebastiano Cutrupi, Patrizia Pizzini, Giovanni Tripepi, Francesca Mallamaci, Carmine Zoccali.

Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1254-63. Case–Control Study of Aspirin Use and Risk of Pancreatic Cancer. Streicher SA, Yu H, Lu L, Kidd MS, Risch HA.

Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):68-74. Aspirin Use and Reduced Risk of Pancreatic Cancer. Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao YT.

FASEB J. 2002 Dec;16(14):1937-9. Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor α-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A4 (LXA4) and ASA-triggered 15-epi-LXA4. Planagumà A, Titos E, López-Parra M, Gaya J, Pueyo G, Arroyo V, Clària J.

Cell Physiol Biochem. 2017;41(4):1313-1324. Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator. Shi C, Zhang N, Feng Y, Cao J, Chen X, Liu B.

J Clin Oncol. 2015 Nov 1;33(31):3591-7. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. Obesity, Aspirin, and Risk of Colorectal Cancer in Carriers of Hereditary Colorectal Cancer: A Prospective Investigation in the CAPP2 Study. Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, Eccles D, Evans DG, Maher ER, Bertario L, Bisgaard ML, Dunlop MG, Ho JW, Hodgson SV, Lindblom A, Lubinski J, Morrison PJ, Murday V, Ramesar RS, Side L, Scott RJ, Thomas HJ, Vasen HF, Burn J, Mathers JC.

Mol Cell Biochem. 1999 Sep;199(1-2):93-102. Antioxidant properties of aspirin: characterization of the ability of aspirin to inhibit silica-induced lipid peroxidation, DNA damage, NF-kappaB activation, and TNF-alpha production. Shi X, Ding M, Dong Z, Chen F, Ye J, Wang S, Leonard SS, Castranova V, Vallyathan V.

Iran J Med Sci. 2016 May;41(3):217-22. Effect of Aspirin on Spinal Cord Injury: An Experimental Study. Kermani HR, Nakhaee N, Fatahian R, Najar AG.

Annals of Oncology, Volume 26, Issue 1, January 2015, Pages 47–57. Estimates of benefits and harms of prophylactic use of aspirin in the general population. J. Cuzick, M. A. Thorat, C. Bosetti, P. H. Brown, J. Burn, N. R. Cook, L. G. Ford, E. J. Jacobs, J. A. Jankowski, C. La Vecchia, M. Law, F. Meyskens, P. M. Rothwell, H. J. Senn, A. Umar.

Oncotarget. 2015 Nov 3;6(34):35157-72. Aspirin, lysine, mifepristone and doxycycline combined can effectively and safely prevent and treat cancer metastasis: prevent seeds from gemmating on soil. Wan L, Dong H, Xu H, Ma J, Zhu Y, Lu Y, Wang J, Zhang T, Li T, Xie J, Xu B, Xie F, Gao Y, Shao J, Tu X, Jia L.

Gynecol Oncol. 2016 Aug;142(2):368-77. Is aspirin use associated with a decreased risk of ovarian cancer? A systematic review and meta-analysis of observational studies with dose-response analysis. Zhang D, Bai B, Xi Y, Wang T, Zhao Y.

Breast Cancer Research volume 19, Article number: 52 (2017). Regular and low-dose aspirin, other non-steroidal anti-inflammatory medications and prospective risk of HER2-defined breast cancer: the California Teachers Study. Christina A. Clarke, Alison J. Canchola, Lisa M. Moy, Susan L. Neuhausen, Nadia T. Chung, James V. Lacey Jr & Leslie Bernstein.

Antioxid Redox Signal. 2017 Dec 10;27(17):1383-1396. Aspirin-Mediated Acetylation Protects Against Multiple Neurodegenerative Pathologies by Impeding Protein Aggregation. Ayyadevara S, Balasubramaniam M, Kakraba S, Alla R, Mehta JL, Shmookler Reis RJ. 

Hepatology. 2010 Apr;51(4):1244-54. Serotonin promotes tumor growth in human hepatocellular cancer. Soll C, Jang JH, Riener MO, Moritz W, Wild PJ, Graf R, Clavien PA.

BMC Medicinevolume 11, Article number: 74 (2013). Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. Michael Berk, Olivia Dean, Hemmo Drexhage, John J McNeil, Steven Moylan, Adrienne O’Neil, Christopher G Davey, Livia Sanna & Michael Maes.

Arch Intern Med. 1993 Nov 8;153(21):2465-71. A reevaluation of aspirin therapy in rheumatoid arthritis. Fries JF, Ramey DR, Singh G, Morfeld D, Bloch DA, Raynauld JP.

Biochem Biophys Res Commun. 2017 May 6;486(3):827-832. Aspirin suppresses the abnormal lipid metabolism in liver cancer cells via disrupting an NFκB-ACSL1 signaling. Yang G, Wang Y, Feng J, Liu Y, Wang T, Zhao M, Ye L, Zhang X.

Drugs R D. 2014 Dec;14(4):233-9. Assessment of the Prophylactic Role of Aspirin and/or Clopidogrel on Experimentally Induced Acute Myocardial Infarction in Hypercholesterolemic Rats. Mohamed AR, El-Hadidy WF, Mannaa HF.

J Clin Invest. 2003 Jul;112(2):222-33. Salicylic acid attenuates virulence in endovascular infections by targeting global regulatory pathways in Staphylococcus aureus. Kupferwasser LI, Yeaman MR, Nast CC, Kupferwasser D, Xiong YQ, Palma M, Cheung AL, Bayer AS.

Cancer Prev Res (Phila). 2017 Feb;10(2):142-152. Unlocking Aspirin’s Chemopreventive Activity: Role of Irreversibly Inhibiting Platelet Cyclooxygenase-1. Lichtenberger LM, Fang D, Bick RJ, Poindexter BJ, Phan T, Bergeron AL, Pradhan S, Dial EJ, Vijayan KV.

Lancet. 2012 Apr 28;379(9826):1591-601. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z.

Eur J Clin Invest. 1999 Feb;29(2):93-9. Aspirin inhibits inducible nitric oxide synthase expression and tumour necrosis factor-alpha release by cultured smooth muscle cells. Sánchez de Miguel L, de Frutos T, González-Fernández F, del Pozo V, Lahoz C, Jiménez A, Rico L, García R, Aceituno E, Millás I, Gómez J, Farré J, Casado S, López-Farré A.

Int J Cancer. 2016 Jul 1;139(1):205-11. Risk of prostate cancer in low-dose aspirin users: A retrospective cohort study. Lapi F, Levi M, Simonetti M, Cancian M, Parretti D, Cricelli I, Sobrero A, Cricelli C.

Br J Cancer. 2016 Mar 29;114(7):819-25. Analgesic medication use and risk of epithelial ovarian cancer in African American women. Peres LC, Camacho F, Abbott SE, Alberg AJ, Bandera EV, Barnholtz-Sloan J, Bondy M, Cote ML, Crankshaw S, Funkhouser E, Moorman PG, Peters ES, Schwartz AG, Terry P, Wang F, Schildkraut JM.

Br J Cancer. 2013 Mar 19;108(5):1178-81. Non-steroidal anti-inflammatory drug and aspirin use and the risk of head and neck cancer. Wilson JC, Murray LJ, Hughes CM, Black A, Anderson LA.

Metab Brain Dis. 2004 Jun;19(1-2):71-7. Aspirin curtails the acetaminophen-induced rise in brain norepinephrine levels. Maharaj H, Maharaj DS, Saravanan KS, Mohanakumar KP, Daya S.

Cell Metab. 2014 Sep 2;20(3):433-47. A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia. Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G, Zechner R, Wagner EF.

Cell Rep. 2014 Apr 24;7(2):514-526. ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis. Forys JT, Kuzmicki CE, Saporita AJ, Winkeler CL, Maggi LB Jr, Weber JD.

J Immunol. 2002 Feb 1;168(3):1428-34. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. Perez-G M, Melo M, Keegan AD, Zamorano J.

Med Sci Sports Exerc. 2001 Dec;33(12):2029-35. Acetylsalicylic acid inhibits the pituitary response to exercise-related stress in humans. Di Luigi L, Guidetti L, Romanelli F, Baldari C, Conte D.

Eur Neurol. 2017;78(5-6):287-289. Aspirin Prophylaxis for Migraine with Aura: An Observational Case Series. Turk WE, Uiterwijk A, Pasmans R, Meys V, Ayata C, Koehler PJ.

Best Pract Res Clin Gastroenterol. 2011 Aug;25(4-5):461-72. Aspirin for the prevention of colorectal cancer. Garcia-Albeniz X, Chan AT.

Circ Res. 1996 May;78(5):759-68. Salicylate or aspirin inhibits the induction of the inducible nitric oxide synthase in rat cardiac fibroblasts. Farivar RS, Chobanian AV, Brecher P.

Am J Physiol Cell Physiol. 2017 Feb 1;312(2):C176-C189. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. Mitrugno A, Sylman JL, Ngo AT, Pang J, Sears RC, Williams CD, McCarty OJ.

Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):1033-41. Analgesic use and sex steroid hormone concentrations in postmenopausal women. Gates MA, Tworoger SS, Eliassen AH, Missmer SA, Hankinson SE.

Fertil Steril. 2001 Apr;75(4):778-84. Aspirin dose dependently inhibits the interleukin-1β–stimulated increase in inducible nitric oxide synthase, nitric oxide, and prostaglandin E2 production in rat ovarian dispersates cultured in vitro. Carnovale DE, Fukuda A, Underhill DC, Laffan JJ, Breuel KF.

Cancer. 2013 Apr 15;119(8):1562-9. Aspirin is associated with lower melanoma risk among postmenopausal Caucasian women: the Women’s Health Initiative. Gamba CA, Swetter SM, Stefanick ML, Kubo J, Desai M, Spaunhurst KM, Sinha AA, Asgari MM, Sturgeon S, Tang JY.

Elife. 2016 May 31;5. pii: e11156. Salicylate, diflunisal and their metabolites inhibit CBP/p300 and exhibit anticancer activity. Shirakawa K, Wang L, Man N, Maksimoska J, Sorum AW, Lim HW, Lee IS, Shimazu T, Newman JC, Schröder S, Ott M, Marmorstein R, Meier J, Nimer S, Verdin E.

European Journal Of Cancer. September 2015Volume 51, Supplement 3, Page S434. 2306 Aspirin and gastro intestinal malignancies; improved survival not only in colorectal cancer? M. Frouws, E. Bastiaannet, M. Van Herk-Sukel, H. Putter, J. Portielje, C. Van De Velde, G.J. Liefers.

J Clin Oncol. 2017 Jun 1;35(16):1836-1844. Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status. Hamada T, Cao Y, Qian ZR, Masugi Y, Nowak JA, Yang J, Song M, Mima K, Kosumi K, Liu L, Shi Y, da Silva A, Gu M, Li W, Keum N, Zhang X, Wu K, Meyerhardt JA, Giovannucci EL, Giannakis M, Rodig SJ, Freeman GJ, Nevo D, Wang M, Chan AT, Fuchs CS, Nishihara R, Ogino S.

PLoS One. 2016 Apr 20;11(4):e0152402. Aspirin in the Treatment of Cancer: Reductions in Metastatic Spread and in Mortality: A Systematic Review and Meta-Analyses of Published Studies. Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, Morris D, Kelson M, Dolwani S.

Br J Cancer. 2012 Apr 24;106(9):1564-70. Use of Aspirin postdiagnosis improves survival for colon cancer patients. Bastiaannet E, Sampieri K, Dekkers OM, de Craen AJ, van Herk-Sukel MP, Lemmens V, van den Broek CB, Coebergh JW, Herings RM, van de Velde CJ, Fodde R, Liefers GJ.

British Journal of Cancer volume 116, pages 405–413 (31 January 2017). Effect of low-dose aspirin use on survival of patients with gastrointestinal malignancies; an observational study. M A Frouws, E Bastiaannet, R E Langley, W K Chia, M P P van Herk-Sukel, V E P P Lemmens, H Putter, H H Hartgrink, B A Bonsing, C J H Van de Velde, J E A Portielje & G J Liefers.

BMC Med. 2013 Mar 18;11:74. doi: 10.1186/1741-7015-11-74. Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O’Neil A, Davey CG, Sanna L, Maes M.

Oncology Times: November 10, 2015 – Volume 37 – Issue 21 – p 5–6. Survival Benefits for Low-Dose Aspirin in GI Cancers. Susman, Ed

Journal of the American College of Surgeons, June 2012Volume 214, Issue 6, Pages 1023–1026. Long-Term Effects of Aspirin on Colorectal Cancer. Carl J. Brown, MD, Steven Gallinger, MD, James Church, MD.

Scientific Reportsvolume 7, Article number: 1875 (2017). NSAIDs Use and Reduced Metastasis in Cancer Patients: results from a meta-analysis. Xiaoping Zhao, Zhi Xu & Haoseng Li

World J Gastrointest Pharmacol Ther. 2014 Feb 6;5(1):40-9. Aspirin, cyclooxygenase inhibition and colorectal cancer. Sostres C, Gargallo CJ, Lanas A.

Cell Biosci. 2018 Jan 4;8:1. Aspirin inhibited the metastasis of colon cancer cells by inhibiting the expression of toll-like receptor 4. Ying J, Zhou HY, Liu P, You Q, Kuang F, Shen YN, Hu ZQ.

Exp Ther Med. 2017 Dec;14(6):5597-5604. Aspirin suppresses TNF‑α‑induced MMP‑9 expression via NF‑κB and MAPK signaling pathways in RAW264.7 cells. Ping Zhang Chao Wu Xiao‑Hui Huang Chen‑Lin Shen Lin Li Wei Zhang Cheng‑Zeng Yao.

J Neurosurg. 2011 Oct;115(4):780-8. Antitumor effect of aspirin in glioblastoma cells by modulation of β-catenin/T-cell factor-mediated transcriptional activity. Lan F, Yue X, Han L, Yuan X, Shi Z, Huang K, Yang Y, Zou J, Zhang J, Jiang T, Pu P, Kang C.

Diabetes. 2012 Apr;61(4):790-6. Salicylate Downregulates 11β-HSD1 Expression in Adipose Tissue in Obese Mice and in Humans, Mediating Insulin Sensitization. Nixon M, Wake DJ, Livingstone DE, Stimson RH, Esteves CL, Seckl JR, Chapman KE, Andrew R, Walker BR.

BMC Cancer volume 15, Article number: 905 (2015). Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein. Jana Koo, Stephanie Cabarcas-Petroski, John L. Petrie, Nicole Diette, Robert J. White & Laura Schramm.

Cell Metab. 2013 Aug 6;18(2):153-61. Cellular Fatty Acid Metabolism and Cancer. Currie E, Schulze A, Zechner R, Walther TC, Farese RV Jr.

J Clin Invest. 2010 Jan;120(1):142-56. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. Samudio I, Harmancey R, Fiegl M, Kantarjian H, Konopleva M, Korchin B, Kaluarachchi K, Bornmann W, Duvvuri S, Taegtmeyer H, Andreeff M.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4370-4375. Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids. Rand AA, Barnych B, Morisseau C, Cajka T, Lee KSS, Panigrahy D, Hammock BD.

Med Hypotheses. 2008;70(2):298-304. Chronic cellular hypoxia as the prime cause of cancer: what is the de-oxygenating role of adulterated and improper ratios of polyunsaturated fatty acids when incorporated into cell membranes? Peskin BS, Carter MJ.

J Clin Invest. 2001 Aug;108(3):437-46. Prevention of fat-induced insulin resistance by salicylate. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, Yuan M, Li ZW, Karin M, Perret P, Shoelson SE, Shulman GI.

PLoS One. 2016; 11(9): e0161218. Aspirin, but Not Tirofiban Displays Protective Effects in Endotoxin Induced Lung Injury. Jessica Tilgner ,Klaus Thilo von Trotha ,Alexander Gombert,Michael J. Jacobs,Maik Drechsler,Yvonne Döring,Oliver Soehnlein,Jochen Grommes.

British Journal of Cancer volume 111, pages 61–67 (01 July 2014). Molecular targets of aspirin and cancer prevention. L Alfonso, G Ai, R C Spitale, G J Bhat.

J Pharmacol Pharmacother. 2011 Jan;2(1):3-6. Evaluation of nootropic and neuroprotective effects of low dose aspirin in rats. Ghosh A, Dhumal VR, Tilak AV, Das N, Singh A, Bondekar AA.

Am J Med. 2012 Jun;125(6):560-7. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R.




You may also like...

6 Responses

  1. Avatar Jay says:

    I wish I had read this article 17 years ago for my mom’s sake. Great article! I believe people are saying K2 is needed to prevent any bleeding from aspirin use. I know your saying it’s overblown, but would K2 which is hard to get the level recommended by food, would effectively solve the bleeding too much fear associated with aspirin?
    Posting problems again. Invalid error. “Invalid captcha value” I don’t know math that well but I think “5” is the answer to +42 = 47.

  2. Avatar Mary says:

    What is the best total mg of daily low dose aspirin? St. Joseph makes 81mg low dose aspirin – is this too low? I’ve also heard you can take 325mg 2x/week instead. Have you heard of this? Which approach is most effective?

    • DanM@cowseatgrass DanM@cowseatgrass says:

      I started with 3 x 100mg daily…I’m not a doctor so I can’t make recommendations, but that seemed to work well for me.

  3. Avatar Greg Lowe says:

    Can you point me to where I can begin to learn about an aspirin regime for me?

Leave a Reply

Your email address will not be published. Required fields are marked *

Please "like" us:Already liked? You can close this